微小残存病変検査の世界市場レポート 2024年

微小残存病変検査の市場規模は近年急速に拡大しています。2023年の14億1,000万米ドルから2024年には16億1,000万米ドルへと、CAGR14.4％で拡大します。この期間の成長は、がん研究の進歩、治療効果のモニタリング需要、微小残存病変検査を裏付ける臨床エビデンスの入手可能性、規制当局の支援、患者の転帰を改善する努力など、いくつかの要因に起因しています。

個別化医療に対する需要の高まりは、微小残存病変検査市場を促進すると予想されます。個別化医療は、遺伝、ライフスタイル、環境などの個人の特性に基づいてヘルスケアの介入を調整し、より良い転帰のために治療を最適化します。微小残存病変検査はこの文脈で極めて重要であり、治療後の残存がん細胞を正確にモニタリングして標的治療を促進します。2022年、食品医薬品局の医薬品評価研究センターは37の新規分子実体を承認し、治療用NMEの約34％、12に相当するものが個別化医療連合によって個別化医薬品に分類されました。このことは、個別化医療に対する需要の高まりと、それが微小残存病変検査市場の成長にプラスの影響を与えていることを浮き彫りにしています。

2023年の微小残存病変検査市場で最大の地域は北米でした。微小残存病変検査市場レポートの対象地域は、アジア太平洋,西欧,東欧,北米,南米,中東,アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 微小残存病変検査市場の特徴

第3章 微小残存病変検査市場の動向と戦略

第4章 微小残存病変検査市場- マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の微小残存病変検査市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 微小残存病変検査市場セグメンテーション

• 世界の微小残存病変検査市場、検査タイプ別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• DNAベースの検査
• RNAベースの検査
• 免疫学的検査
• 世界の微小残存病変検査市場、技術別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• フローサイトメトリー
• ポリメラーゼ連鎖反応（PCR）
• 次世代シーケンス（NGS）
• その他の技術
• 世界の微小残存病変検査市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 血液悪性腫瘍
• 白血病
• リンパ腫
• 固形腫瘍
• その他の用途
• 世界の微小残存病変検査市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院と専門クリニック
• 診断研究所
• 学術研究機関
• その他のエンドユーザー

第7章 微小残存病変検査市場の地域および国分析

• 世界の微小残存病変検査市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の微小残存病変検査市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋の微小残存病変検査市場

第9章 中国の微小残存病変検査市場

第10章 インドの微小残存病変検査市場

第11章 日本の微小残存病変検査市場

第12章 オーストラリアの微小残存病変検査市場

第13章 インドネシアの微小残存病変検査市場

第14章 韓国の微小残存病変検査市場

第15章 西欧の微小残存病変検査市場

第16章 英国の微小残存病変検査市場

第17章 ドイツの微小残存病変検査市場

第18章 フランスの微小残存病変検査市場

第19章 イタリアの微小残存病変検査市場

第20章 スペインの微小残存病変検査市場

第21章 東欧の微小残存病変検査市場

第22章 ロシアの微小残存病変検査市場

第23章 北米の微小残存病変検査市場

第24章 米国の微小残存病変検査市場

第25章 カナダの微小残存病変検査市場

第26章 南米の微小残存病変検査市場

第27章 ブラジルの微小残存病変検査市場

第28章 中東の微小残存病変検査市場

第29章 アフリカの微小残存病変検査市場

第30章 微小残存病変検査市場の競合情勢と企業プロファイル

• 微小残存病変検査市場の競合情勢
• 微小残存病変検査市場の企業プロファイル
  • Natera Inc.
  • Guardant Health Inc.
  • Laboratory Corporation of America Holdings
  • QIAGEN NV
  • F. Hoffmann-La Roche Ltd.

第31章 世界の微小残存病変検査市場の競合ベンチマーキング

第32章 世界の微小残存病変検査市場競争ダッシュボード

第33章 微小残存病変検査市場における主要な合併と買収

第34章 微小残存病変検査市場の将来展望と可能性分析

第35章 付録

“Minimal Residual Disease Testing Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on minimal residual disease testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for minimal residual disease testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The minimal residual disease testing market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Test Type: DNA - Based Test; RNA- Based Test; Immunological Test
• 2) By Technology: Flow Cytometry; Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Other Technologies
• 3) By Application: Hematological Malignancies; Leukemia; Lymphoma; Solid Tumors; Other Application
• 4) By End User: Hospitals And Specialty Clinics; Diagnostic Laboratories; Academic and Research Institutes; Other End Users
• Companies Mentioned: Natera Inc.; Guardant Health Inc.; Laboratory Corporation of America Holdings; QIAGEN NV; F. Hoffmann-La Roche Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Minimal residual disease testing involves highly sensitive tests aimed at detecting cancer cells that may persist in a patient's body after treatment. This type of testing is crucial for monitoring the effectiveness of cancer treatment and guiding future treatment strategies.

The main types of tests for minimal residual disease testing include DNA-based tests, RNA-based tests, and immunological tests. DNA-based testing, also known as genetic testing, is a medical examination designed to identify changes in chromosomes, genes, or proteins. Various technologies, such as flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others, are employed in applications such as hematological malignancies, leukemia, lymphoma, solid tumors, and more. These tests are utilized by hospitals and specialty clinics, diagnostic laboratories, academic and research institutes, and other healthcare entities.

The minimal residual disease testing market research report is one of a series of new reports from The Business Research Company that provides minimal residual disease testing market statistics, including minimal residual disease testing industry global market size, regional shares, competitors with a minimal residual disease testing market share, detailed minimal residual disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the minimal residual disease testing industry. This minimal residual disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The minimal residual disease testing market size has grown rapidly in recent years. It will grow from $1.41 billion in 2023 to $1.61 billion in 2024 at a compound annual growth rate (CAGR) of 14.4%. The historical period's growth can be attributed to several factors, including advancements in cancer research, the demand for monitoring treatment efficacy, the availability of clinical evidence supporting minimal residual disease testing, regulatory support, and efforts to improve patient outcomes.

The minimal residual disease testing market size is expected to see rapid growth in the next few years. It will grow to $2.62 billion in 2028 at a compound annual growth rate (CAGR) of 12.9%. The anticipated growth in the forecast period can be attributed to factors such as the increasing incidence of cancer, therapeutic advancements, trends in precision medicine, a shift toward early detection practices, and the integration of healthcare systems. Major trends in the forecast period encompass the integration of liquid biopsy approaches, a heightened focus on the early detection of relapse, the expansion of minimal residual disease (MRD) testing in clinical trials, increasing adoption in pediatric oncology, and collaborations for research and development initiatives.

The anticipated increase in cancer cases is set to drive the growth of the minimal residual disease testing market. Cancer, characterized by uncontrolled cell growth and spread in the body, is primarily diagnosed and monitored through minimal residual disease testing-a highly sensitive method detecting residual cancer cells. This testing aids in the early-stage prevention of cancer, contributing to the expansion of the minimal residual disease testing market. For example, the American Cancer Society Inc. reported an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths in the United States in 2022, emphasizing the critical role of minimal residual disease testing in managing cancer.

The growing demand for personalized medicine is expected to propel the minimal residual disease testing market. Personalized medicine tailors healthcare interventions based on individual characteristics such as genetics, lifestyle, and environment, optimizing treatments for better outcomes. Minimal residual disease testing is crucial in this context, precisely monitoring residual cancer cells post-treatment to facilitate targeted therapies. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research approved 37 new molecular entities, and approximately 34% of therapeutic NMEs, equivalent to 12, were classified as personalized medicines by the Personalized Medicine Coalition. This highlights the increasing demand for personalized medicine and its positive impact on the growth of the minimal residual disease testing market.

Product innovation emerges as a prominent trend in the minimal residual disease testing market, with major companies introducing new solutions to maintain their market positions. Twist Bioscience, a US-based synthetic biology and genomics company, launched the Twist MRD Panel in 2022, aiming to advance research and development in minimal residual disease detection in cancer screening. This customizable panel of genes is designed to detect very low levels of residual cancer cells in a patient's blood, offering flexibility and integration into next-generation sequencing workflows.

Major companies in the minimal residual disease testing market are also focusing on cancer research testing solutions to enhance detection sensitivity, improve treatment monitoring, and advance precision medicine approaches. For instance, Integrated DNA Technologies (IDT), a US-based genomic solutions provider, introduced the IDT Archer FUSIONPlex Core Solid Tumor Panel in April 2023. This enhanced cancer research testing solution simplifies fusion detection and variant calling in solid tumors, providing researchers with a scalable, user-friendly solution that saves time and resources.

In August 2021, Illumina Inc., a US-based biotechnology company, acquired GRAIL for $8 billion. This strategic move aimed to enhance patient access to a life-saving multi-cancer early-detection test utilizing next-generation sequencing testing technology and minimal residual disease testing, thereby expanding health services globally.

Major companies operating in the minimal residual disease testing market report are Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A

North America was the largest region in the minimal residual disease testing market in 2023. The regions covered in the minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the minimal residual disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The minimal residual disease testing market includes revenues earned by entities by providing services such as peripheral blood cell testing, sequencing testing, high-throughput sequencing testing, and methylation sequencing testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Minimal Residual Disease Testing Market Characteristics

3. Minimal Residual Disease Testing Market Trends And Strategies

4. Minimal Residual Disease Testing Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Minimal Residual Disease Testing Market Size and Growth

• 5.1. Global Minimal Residual Disease Testing Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Minimal Residual Disease Testing Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Minimal Residual Disease Testing Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Minimal Residual Disease Testing Market Segmentation

• 6.1. Global Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• DNA - Based Test
• RNA- Based Test
• Immunological Test
• 6.2. Global Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Other Technologies
• 6.3. Global Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hematological Malignancies
• Leukemia
• Lymphoma
• Solid Tumors
• Other Application
• 6.4. Global Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals And Specialty Clinics
• Diagnostic Laboratories
• Academic and Research Institutes
• Other End Users

7. Minimal Residual Disease Testing Market Regional And Country Analysis

• 7.1. Global Minimal Residual Disease Testing Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Minimal Residual Disease Testing Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Minimal Residual Disease Testing Market

• 8.1. Asia-Pacific Minimal Residual Disease Testing Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Minimal Residual Disease Testing Market

• 9.1. China Minimal Residual Disease Testing Market Overview
• 9.2. China Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Minimal Residual Disease Testing Market

• 10.1. India Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Minimal Residual Disease Testing Market

• 11.1. Japan Minimal Residual Disease Testing Market Overview
• 11.2. Japan Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Minimal Residual Disease Testing Market

• 12.1. Australia Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Minimal Residual Disease Testing Market

• 13.1. Indonesia Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Minimal Residual Disease Testing Market

• 14.1. South Korea Minimal Residual Disease Testing Market Overview
• 14.2. South Korea Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Minimal Residual Disease Testing Market

• 15.1. Western Europe Minimal Residual Disease Testing Market Overview
• 15.2. Western Europe Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Minimal Residual Disease Testing Market

• 16.1. UK Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Minimal Residual Disease Testing Market

• 17.1. Germany Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Minimal Residual Disease Testing Market

• 18.1. France Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Minimal Residual Disease Testing Market

• 19.1. Italy Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Minimal Residual Disease Testing Market

• 20.1. Spain Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Minimal Residual Disease Testing Market

• 21.1. Eastern Europe Minimal Residual Disease Testing Market Overview
• 21.2. Eastern Europe Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Minimal Residual Disease Testing Market

• 22.1. Russia Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Minimal Residual Disease Testing Market

• 23.1. North America Minimal Residual Disease Testing Market Overview
• 23.2. North America Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Minimal Residual Disease Testing Market

• 24.1. USA Minimal Residual Disease Testing Market Overview
• 24.2. USA Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Minimal Residual Disease Testing Market

• 25.1. Canada Minimal Residual Disease Testing Market Overview
• 25.2. Canada Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Minimal Residual Disease Testing Market

• 26.1. South America Minimal Residual Disease Testing Market Overview
• 26.2. South America Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Minimal Residual Disease Testing Market

• 27.1. Brazil Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Minimal Residual Disease Testing Market

• 28.1. Middle East Minimal Residual Disease Testing Market Overview
• 28.2. Middle East Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Minimal Residual Disease Testing Market

• 29.1. Africa Minimal Residual Disease Testing Market Overview
• 29.2. Africa Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Minimal Residual Disease Testing Market Competitive Landscape And Company Profiles

• 30.1. Minimal Residual Disease Testing Market Competitive Landscape
• 30.2. Minimal Residual Disease Testing Market Company Profiles
  • 30.2.1. Natera Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Guardant Health Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Laboratory Corporation of America Holdings
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. QIAGEN NV
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. F. Hoffmann-La Roche Ltd.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Minimal Residual Disease Testing Market Competitive Benchmarking

32. Global Minimal Residual Disease Testing Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Minimal Residual Disease Testing Market

34. Minimal Residual Disease Testing Market Future Outlook and Potential Analysis

• 34.1 Minimal Residual Disease Testing Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Minimal Residual Disease Testing Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Minimal Residual Disease Testing Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer